• Begum Aygen Gumus, Ali Emre Sevik, and Sevil Alkan.
• Bratisl Med J. 2024 Jan 1; 125 (10): 589596589-596.

ObjectiveGiven the multisystem nature of COVID-19 and its potential neuro-psychiatric effects along with the recognized role of systemic inflammation in the prognosis of both COVID-19 and psychiatric disorders, it is imperative to assess psychiatric symptoms in COVID-19 patients. This study sought to investigate the value of systemic immune-inflammation index (SII) scores, levels of anxiety and depressive symptoms assessed within the initial 24 hours following COVID-19 diagnosis as potential predictors of the clinical trajectory of COVID-19.MethodsThis study involved 64 patients admitted to our COVID-19 ward with mild-to-moderate COVID-19 pneumonia, all of whom underwent a psychiatric evaluation within 24 hours of admission. Upon admission, levels of c-reactive protein and inflammatory markers including leukocyte, neutrophil, thrombocyte, and lymphocyte counts were measured to calculate individual SII scores. Psychiatric evaluations were conducted using the State-Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HDRS), and Standardized Mini-Mental Test (SMMT).ResultsThe patients with clinical deterioration of COVID-19 exhibited higher STAI-Trait and STAI-State subscale scores measured upon admission compared to those without clinical deterioration. HDRS scores showed no significant correlation with clinical deterioration. STAI-State subscale scores correlated with SII scores and the duration of hospital stay. High baseline STAI scores and SII scores predicted COVID-19 clinical deterioration.ConclusionOur study demonstrated that the initial SII and STAI scores assessed within the initial 24 hours of hospitalization for COVID-19 significantly predicted the clinical progression of the disease during the hospital stay (Tab. 5, Ref. 37). Text in PDF www.elis.sk Keywords: COVID-19, systemic inflammatory response index, disease severity, inflammation.

21 keywords...

hide…